Inhibition of platelet aggregation by tartrazine and a pyrazolone analogue in normal and allergic individuals

Authors

  • J. S. GALLAGHER,

    Corresponding author
    1. Division of Immunology, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, U.S.A.
      Dr J. S. Gallagher, Ph.D., University of Cincinnati, Medical Center, Division of Immunology, 231 Bethesda Avenue, Cincinnati, Ohio 45267, U.S.A.
    Search for more papers by this author
  • G. L. SPLANSKY,

    1. Division of Immunology, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, U.S.A.
    Search for more papers by this author
  • I. L. BERNSTEIN

    1. Division of Immunology, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, U.S.A.
    Search for more papers by this author

Dr J. S. Gallagher, Ph.D., University of Cincinnati, Medical Center, Division of Immunology, 231 Bethesda Avenue, Cincinnati, Ohio 45267, U.S.A.

Summary

The effect of tartrazine (T) (yellow dye No. 5) and one of its metabolites an aminopyrazolone analogue (1-sulphophenyl-3-carboxy-5-hydroxypyruzole, SCHP) upon collagen-induced platelet aggregation (C-PA) was investigated in fourteen atopic patients and fourteen normal subjects. Both T and SCHP inhibited C-PA in atopic patients at significantly lower doses than in normal volunteers. The mean inhibitory concentrations of SCHP were similar to aspirin in both atopic and normal individuals. Although the precise mechanism by which these chemicals block C-PA has not been elucidated, this in vitro system may be a useful method of assessing non-immune mechanisms involved in reactions to tartrazine.

Ancillary